MILFORD, Mass., Jan. 28, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RNA viruses, today announced that Douglas J. Jensen, President and CEO, will present at the 17th annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 9:00 am Eastern Time.
The BIO CEO & Investor Conference is being held at the Waldorf Astoria Hotel in New York City on February 9 and 10, 2015.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical stage drug discovery company. Based on its proprietary platform technology, Spring Bank is developing a pipeline of products representing a new class of pharmaceuticals called small molecule nucleic acid hybrids (SMNH), with a wide range of applications and multi-billion dollar market potential. These rationally designed molecules combine the selectivity of naturally occurring nucleotides, with the drug like properties of classical pharmaceuticals. These SMNHs have the properties of oral delivery, good pharmacokinetics, low side effects and ease of manufacture. The Company's most advanced drug candidate is SB 9200, a potential breakthrough for the treatment of a wide range of RNA viruses including HBV, RSV, and HCV, works by up-regulating the host immune response in the presence of viral infection. Spring Bank has a robust pre-clinical pipeline behind SB 9200, with programs in Norovirus, COPD and cancer.
Douglas J. Jensen
President and Chief Executive Officer
(508) 473-5993 x105
SOURCE Spring Bank Pharmaceuticals, Inc.